Anzeige
+++Weltverbesserer-Aktie startet durch: Rekordumsatz von 42,5 Mio. USD im Geschäftsjahr+++
Portfolio Tracker
Alle Depots an einem Ort. Dein Gesamtvermögen immer im Blick, tiefgründige Renditeanalysen und Dividendenplaner.
Anzeige
EQS-News

Latvian Companies and Researchers Sign Defense Technology and Genomics Agreements as LIAA US Trade Mission Concludes 30.09.2026, 14:05 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Investment and Development Agency of Latvia (LIAA) / Key word(s): Contract
Latvian Companies and Researchers Sign Defense Technology and Genomics Agreements as LIAA US Trade Mission Concludes

30.09.2026 / 14:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


RIGA, Latvia, Sept. 30, 2026 /PRNewswire/ -- A Latvian business trade mission to the United States organized by the Investment and Development Agency of Latvia (LIAA) has concluded with new cooperation agreements in defense technology and genomics. Held during the working visit of President of Latvia Edgars Rinkēvičs, the mission brought together 44 Latvian companies and organizations across four sector tracks in New York, Los Angeles and San Diego: startups, the film industry, defense and dual-use technologies, and biomedicine and pharmaceuticals.

President of Latvia Edgars Rinkēvičs and the Latvian biomedicine delegation visit DNA sequencing technology company Illumina in San Diego for the signing of a Memorandum of Understanding.

"The United States is a strategic market for Latvia. These agreements show that our companies and researchers can compete internationally with technology, expertise and manufacturing capabilities. We now expect this cooperation to deliver projects, orders and investment," said Raivis Bremšmits, State Secretary at the Ministry of Economics.

In defense and dual-use technologies, ORIGIN Robotics and Anduril signed a memorandum of understanding on cooperation in counter-UAS air defense for NATO's eastern flank, including technology integration, testing and demonstrations in Latvia.

The Latvian delegation also met with representatives of Neros, Shield AI, Kratos Defense & Security Solutions, Qualcomm, Axon and Analog Devices. President Rinkēvičs discussed a potential cooperation framework between Analog Devices, SAF Tehnika and Riga Technical University. Latvian participants presented capabilities in autonomous systems, secure communications, sensors, engineering and manufacturing, as well as locally developed energy solutions that could strengthen European supply resilience.

In San Diego, the National Institute for Research and Innovations signed a memorandum with Element Biosciences to explore, test and develop new genomic technologies in Latvia. Illumina signed a separate memorandum with six Latvian institutions: the National Institute for Research and Innovations, Riga East University Hospital, Pauls Stradiņš Clinical University Hospital, Children's Clinical University Hospital, Rīga Stradiņš University and the University of Latvia. The agreement provides a framework for advancing genomics, precision medicine and the use of modern biomedical technologies to improve patient outcomes.

In Los Angeles, Latvian film industry representatives met with Paramount Pictures, Warner Bros. Discovery, The Walt Disney Company, Lionsgate, Blumhouse Productions, Ketchup Entertainment and Netflix. Discussions focused on filming in Latvia, international co-productions, animation, post-production and content distribution.

In New York, Latvian startups met with US investors and ServiceNow representatives and presented their solutions at the 'Pitch to a President' event.

"The memoranda are the mission's most visible result, but its real value will be measured by the projects, investment and exports that follow. LIAA will continue working with the participants after the mission," said Ieva Jāgere, Director General of LIAA.

Participation in the trade mission was organized by LIAA under the EU co-funded program for the development of innovative entrepreneurship by small and medium-sized enterprises, supported by the European Regional Development Fund and national funding.

 

Investment and Development Agency of Latvia Logo

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/latvian-companies-and-researchers-sign-defense-technology-and-genomics-agreements-as-liaa-us-trade-mission-concludes-302894085.html

rt.gif?NewsItemId=EN60250&Transmission_Id=202609300800PR_NEWS_EURO_ND__EN60250&DateId=20260930


30.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2408020  30.09.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer